AA
NERV icon

ALPS Advisors’s Minerva Neurosciences NERV Stock Holding History

ALPS Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,725
Closed -$603K – 845
2019
Q3 		$603K Sell
9,725
-485
-5% -$27.5K ﹤0.01% 466
2019
Q2 		$460K Sell
10,210
-1,526
-13% -$76.4K ﹤0.01% 554
2019
Q1 		$738K Buy
11,736
+508
+5% +$30.5K 0.01% 398
2018
Q4 		$605K Buy
11,228
+2,651
+31% +$194K ﹤0.01% 435
2018
Q3 		$861K Buy
8,577
+1,547
+22% +$116K 0.01% 439
2018
Q2 		$464K Buy
7,030
+542
+8% +$32.9K ﹤0.01% 661
2018
Q1 		$324K Buy
6,488
+1,127
+21% +$54.2K ﹤0.01% 808
2017
Q4 		$259K Buy
5,361
+128
+2% +$6.35K ﹤0.01% 765
2017
Q3 		$318K Buy
5,233
+1,092
+26% +$62.6K ﹤0.01% 724
2017
Q2 		$293K Buy
4,141
+398
+11% +$25.8K ﹤0.01% 722
2017
Q1 		$243K Sell
3,743
-438
-10% -$34K ﹤0.01% 704
2016
Q4 		$393K Buy
+4,181
New +$427K ﹤0.01% 604

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ALPS Advisors's NERV Position: Q4 2019 in Review

ALPS Advisors sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 9,725 shares — an estimated $603K sold.

ALPS Advisors first reported a position in NERV in Q4 2016 and held it in 12 quarters. The position peaked at $861K in Q3 2018. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

  • ALPS Advisors reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
  • ALPS Advisors sold 9,725 Minerva Neurosciences shares in Q4 2019, an estimated $603K.
  • ALPS Advisors first reported a position in Minerva Neurosciences in Q4 2016 and held it in 12 quarters.
  • ALPS Advisors's Minerva Neurosciences position peaked at $861K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.